Company Information

SUVEN LIFE SCIENCES LTD.

NSE : SUVENBSE : 530239ISIN CODE : INE495B01038Industry : Pharmaceuticals & DrugsHouse : Private
BSE114.511.91 (+1.7 %)
PREV CLOSE ( ) 112.60
OPEN PRICE ( ) 118.23
BID PRICE (QTY) 114.55 (121)
OFFER PRICE (QTY) 114.69 (66)
VOLUME 112546
TODAY'S LOW / HIGH ( )113.96 118.23
52 WK LOW / HIGH ( )55.01 128.79
NSE114.702.25 (+2 %)
PREV CLOSE( ) 112.45
OPEN PRICE ( ) 117.95
BID PRICE (QTY) 114.70 (693)
OFFER PRICE (QTY) 114.75 (230)
VOLUME 474106
TODAY'S LOW / HIGH( ) 114.05 118.05
52 WK LOW / HIGH ( )55.1 129
ChairmanVenkateswarlu Jasti
Company SecretaryShrenik Soni
Non Executive DirectorSeyed E Hasnain
Independent DirectorVajja Sambasiva Rao
Independent Non-Executive DirectorSantanu Mukherjee
JAS Padmaja
Whole Time DirectorSudha Rani Jasti
Incorporation Year : 09-03 1989

Registered Office :

Address : 8-2-334, S D E Serene Chambers,6th Floor, Road No 5, Avenue 7,Banjara Hills Hyderabad,
Telangana-500034 .

Phone : 040- 23541142 /3315 / 23543311

Email :  info@suven.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.